Our group is currently involved as partner in three major projects, described below.
BigMed is an ambitious project aiming to identify and address the barriers to Precision Medicine in Norway. Funded by the Norwegian Research Council (IKTPLUSS Lighthouse) and a handful of dedicated partners, the projects aims to create a platform for further leaps and help nourish an expanding ecosystem of partners from the clinical, academic and commercial worlds.
BigMed’s main objective is to identify and address the bottlenecks in precision medicine. Specifically, this means developing and demonstrating implementation tools that create value for patients and clinicians alike. Each of the four clinical focus areas in BigMed has different needs that are addressed by the development of different tools. For monogenic diseases, standardized patient phenotyping and data sharing are very important for increasing the diagnostic quality. Our research group collaborates with SciLifeLab, DIPS and DNV GL to develop phenotyping tools, variant databases and data sharing solutions based on standards developed by the Global Alliance for Genomics and Health (GA4GH).
Dag E. Undlien is a partner in BigMed; Yngve Sejersted (associated group member) and Tony Håndstad are work package leaders.
ICT platform for personalized medicine (GeniOUS)
The project ICT platform for personalized medicine (GeniOUS) aims to develop solutions for the efficient and safe use of genetic high-throughput sequencing data in diagnostics and translational research, with a particular focus on involving the patients themselves. The project involves further development of ELLA (software for interpretation of genetic variants), the Pharmacolyzer (a solution for pharmacogenomics), as well as solutions for communication between patients and the health care system, health economic analyses and suggesting refinements to existing legal frameworks for the use of HTS data.
GeniOUS is funded by the Research Council of Norway (IKTPLUSS program), with Dag E. Undlien as principle investigator.
Application of sequencing data to tailor medical treatments
The introduction of whole-genome sequencing in clinical practice has opened a path for pre-emptive pharmacogenomic (PGx) testing. PGx is the study of how genetics influences medication of patients. Funded by a grant from the South-Eastern Norway Regional Health Authority and BigMed, and in collaboration with Electronic Health Record vendor DIPS and the Department of Pharmacy, UiO, this project seeks to develop an end-to-end automated pharmacogenomics pipeline that can deliver actionable reports to openEHR-based systems with the aim of tailoring drug treatment to each patient’s genotype.